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Breast cancer risk in women is strongly associated with both ge-
netic and environmental factors. The discovery of the breast can-
cer susceptibility genes, breast cancer 1, early onset (BRCA1) and 
breast cancer 2, early onset (BRCA2), and a decade of subsequent 
clinical research led to substantial positive impact on the health of 
women  affected  with  the  Mendelian  cancer  predisposition 
syndromes, conferred by germline mutations in these genes (1–3). 
However,  much  of  the  familial  aggregation  of  breast  cancer 
remains unexplained. Building on previous work suggesting the 
existence of substantial polygenic influences on breast cancer risk 
(4), recent genome-wide association studies (5–10), and a candi-
date  gene  association  study  (11),  have  demonstrated  that  an 
expanding set of single-nucleotide polymorphisms (SNPs) are re-
producibly associated with breast cancer risk in women of European 
ancestry, and in some cases, in women from other racial or ethnic 
backgrounds.
As with other disorders with complex inheritance, like prostate 
cancer, Crohn’s disease, and hypercholesterolemia (12–15), the 
discovery and validation of SNPs associated with breast cancer risk 
have created an opportunity to explore whether a panel of SNPs 
can be used to predict disease risk and to assess the clinical rele-
vance of such a panel. In the context of breast cancer, the assess-
ment of invasive cancer risk has important clinical implications 
that can affect decisions about appropriate counseling, screening 
regimens, and risk reduction strategies (3,16–20). Thus, improve-
ments in risk prediction have the potential to affect clinical care if 
they are demonstrated to have clinical validity and utility.
For sporadic (nonfamilial) breast cancer, the Gail model (21) 
has been commonly used to produce individual risk estimates in 
women. The model incorporates individual risk factors including 
age,  family  history  (breast  cancer  among  first-degree  relatives), 
personal reproductive history (age at menarche and at first live 
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  Background  The Gail model is widely used for the assessment of risk of invasive breast cancer based on recognized clinical 
risk factors. In recent years, a substantial number of single-nucleotide polymorphisms (SNPs) associated with 
breast cancer risk have been identified. However, it remains unclear how to effectively integrate clinical and 
genetic risk factors for risk assessment.
  Methods  Seven SNPs associated with breast cancer risk were selected from the literature and genotyped in white non-
Hispanic women in a nested case–control cohort of 1664 case patients and 1636 control subjects within the 
Women’s Health Initiative Clinical Trial. SNP risk scores were computed based on previously published odds 
ratios assuming a multiplicative model. Combined risk scores were calculated by multiplying Gail risk estimates 
by  the  SNP  risk  scores.  The  independence  of  Gail  risk  and  SNP  risk  was  evaluated  by  logistic  regression. 
Calibration of relative risks was evaluated using the Hosmer–Lemeshow test. The performance of the combined 
risk scores was evaluated using receiver operating characteristic curves. The net reclassification improvement 
(NRI) was used to assess improvement in classification of women into low (<1.5%), intermediate (1.5%–2%), and 
high (>2%) categories of 5-year risk. All tests of statistical significance were two-sided.
  Results  The SNP risk score was nearly independent of Gail risk. There was good agreement between predicted and 
observed SNP relative risks. In the analysis for receiver operating characteristic curves, the combined risk score 
was more discriminating, with area under the curve of 0.594 compared with area under the curve of 0.557 for 
Gail risk alone (P < .001). Classification also improved for 5.6% of case patients and 2.9% of control subjects, 
showing an NRI value of 0.085 (P = 1.0 × 1025). Focusing on women with intermediate Gail risk resulted in an 
improved NRI of 0.195 (P = 8.6 × 1025).
  Conclusions  Combining validated common genetic risk factors with clinical risk factors resulted in modest improvement in 
classification of breast cancer risks in white non-Hispanic postmenopausal women. Classification performance 
was further improved by focusing on women at intermediate risk.
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birth), and personal medical history (number of previous breast 
biopsies and presence of biopsy-confirmed atypical hyperplasia) to 
estimate the 5-year risk and lifetime risk of invasive breast cancer 
in an individual. The model uses relative risk calculation based on 
logistic regression of these risk factors, followed by conversion to 
absolute risk based on epidemiological data for breast cancer inci-
dence  and  competing  risks.  A  projected  Gail  5-year  risk  score 
(5-year absolute risk of breast cancer diagnosis) of greater than or 
equal to 1.66% is an important tool to identify women who have 
an increased risk of developing breast cancer and may benefit from 
risk reduction with selective estrogen receptor (ER) modulators 
(19,20). Therefore, this model has implications for primary pre-
vention of invasive breast cancer. However, both the discrimina-
tory  accuracy  of  the  Gail  model  and  its  calibration  in  certain 
populations have been challenged (22223), and uptake of primary 
prevention  strategies  among  physicians  caring  for  women  at 
increased risk for sporadic breast cancer has been modest (24).
Two  previous  studies  have  analyzed  the  potential  impact  of 
adding genetic information from a panel of seven SNPs associated 
with breast cancer risk to the Gail model (25,26). One analysis 
used receiver operating characteristic (ROC) curves to predict that 
the area under the curve (AUC) would improve from 0.607 for the 
Gail  model  alone,  as  implemented  in  the  National  Cancer 
Institute’s  Breast  Cancer  Risk  Assessment  Tool  (BCRAT),  to 
0.632 when risk information from the seven SNPs was combined 
with the Gail model (BCRATplus7) (25). In an editorial accompa-
nying that article (25), Pepe and Janes (27) suggested that ROC 
curve analysis might not be the most useful method for assessing 
performance of these models and that reclassification tables would 
allow the assessment of the fraction of individuals with meaningful 
improvements in risk prediction. A second analysis showed that 
real gains, albeit modest, could be achieved in reclassification of 
risk, under the assumption that the model combining information 
from the seven SNPs with the Gail model was well calibrated (26).
In addition, other studies have begun to set modest expecta-
tions for potential clinical gains from combining SNP information 
with clinical risk factors (25,26,28,29). However, these studies have 
either  been  theoretical  in  nature  (25,26,28)  or  they  combined 
model building with evaluation (29), which may complicate evalu-
ating the results in clinical context. We set out to empirically assess 
the clinical validity of a prespecified model combining genetic in-
formation with risk estimates from the Gail model in a nested 
case–control study from the Women’s Health Initiative (WHI) 
Clinical Trial (30). We also assessed whether the improvement in 
risk assessment from incorporating genetic information might be 
larger in subsets of women at intermediate risk based on clinical 
risk  factors.  We  focused  our  analyses  on  white  non-Hispanic 
women because of the combined availability of Gail model validity 
information and accurate odds ratios for SNPs in this group.
Subjects and Methods
Ascertainment of Case Patients and Control Subjects
Of 68 132 participants, we identified 2166 women who developed 
invasive breast cancer between random assignment (September 1, 
1993, to December 31, 1998) and the originally planned end of the 
intervention phase (March 31, 2005) of the WHI Clinical Trial 
(30). We matched one control subject without a cancer diagnosis 
for each case patient for baseline age at enrollment in the WHI 
Clinical Trial, self-reported ethnicity, trial intervention (hormone 
replacement therapy, dietary modification, or calcium and vitamin 
D supplementation), years since trial randomization, and whether 
or not they had had a hysterectomy. Written informed consent was 
obtained from each participant, and the study was approved by the 
Fred Hutchinson Cancer Research Center’s Institutional Review 
Board. Participants in the WHI Clinical Trial had an opportunity 
to opt in or out of any collaboration involving commercial entities 
because some women may prefer not to participate in research 
involving commercial (as opposed to nonprofit) entities. We re-
stricted our analyses to the subset of these case patients and control 
subjects that had consented for collaborations involving commer-
cial entities. Approximately, 84% of all eligible case patients and 
control subjects provided such consent. The interventions used in 
the WHI Clinical Trial are independent of baseline genetic and 
clinical risk factors by study design (30), so the analyses presented 
here were not stratified by trial intervention. In this nested case–
control study, we focused our analyses on 3300 white non-Hispanic 
women, representing 87% of the matched case patients and control 
subjects.
Estimation of Gail Risk Score
We used the Gail model to estimate the 5-year absolute risk of 
breast cancer (“Gail risk”) based on age, ethnicity, age at men-
arche, age at birth of first child, number of first-degree relatives 
with breast cancer, and the number of previous breast biopsies. We 
did not have information on biopsy histopathology (ie, whether 
CONTEXT AND CAVEATS
Prior knowledge
It  is  not  known  whether  adding  genotyping  data  from  single- 
nucleotide polymorphisms (SNPs) associated with breast cancer 
risk to the Gail model of breast cancer risk results in clinical gains.
Study design
Composite SNP relative risk scores (SNP risk) using genotyping 
data from seven SNPs previously associated with breast cancer 
risk were estimated among participants in a case–control study of 
white non-Hispanic postmenopausal women within the Women’s 
Health Initiative Clinical Trial. The SNP risk estimates were com-
bined multiplicatively with risk estimates from the Gail model and 
compared with the estimates from the Gail model.
Contribution
Breast cancer risk was more accurately estimated by combining 
Gail risk estimates and SNP risk.
Implications
The combined risk assessment model has clinical validity in white 
non-Hispanic postmenopausal women.
Limitations
The scope of this study at present is limited to white non-Hispanic 
postmenopausal women who share clinical characteristics of the 
women used in this cohort.
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atypical hyperplasia was present), and this was coded as “unknown.” 
We computed Gail risk for the subjects using a reimplementation 
of the current BCRAT version 2, based on program source code 
downloaded from the National Cancer Institute Web site (http:/
/www.cancer.gov/bcrisktool/) on August 7, 2008.
SNP Selection and SNP Risk Score
In our model, we included SNPs that showed statistically signifi-
cant associations with breast cancer risk in a genome-wide associ-
ation study with correction for multiple testing and were confirmed 
in an independent set of case patients and control subjects. Seven 
SNPs were found to meet these criteria at the time that the study 
was initiated (5–8). Our model for SNP risk was based on allele 
frequencies and effect sizes (odds ratios) reported in these original 
studies (Table 1).
We defined an individual’s composite SNP relative risk score 
(“SNP risk”) as the product of genotype relative risk values for the 
seven SNPs. Based on a log-additive risk model, the three geno-
types AA, AB, and BB for a single SNP have relative risk values of 
1, OR, and OR
2, under a rare disease model, where OR is the pre-
viously reported disease odds ratio for the high-risk allele, B, vs the 
low-risk allele, A (Table 1). If the B allele has frequency p, then 
these genotypes have population frequencies of (1 2 p)
2, 2p(1 2 p), 
and  p
2,  assuming  Hardy–Weinberg  equilibrium.  We  scaled  the 
genotype relative risk values for each SNP so that based on these 
frequencies  the  average  relative  risk  in  the  population  is  1. 
Specifically,  given  the  unscaled  population  average  relative  risk   
(µ) = (1 2 p)
2 + 2p(1 2 p)OR + p
2OR
2, we used the adjusted risk 
values  1/µ,  OR/µ,  and  OR
2/µ  for  AA,  AB,  and  BB  genotypes. 
Missing genotypes were assigned a relative risk of 1.
Combined Gail × SNP Risk Score
The formula for our combined 5-year Gail × SNP absolute risk 
score is:
1 2 3 4 5 6 7
[Gail SNP risk]
[Gail risk] SNP SNP SNP SNP SNP SNP SNP ,
×
= ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅
where Gail is the Gail absolute risk score, and SNP1 to 7 are relative 
risk scores for the individual SNPs, each scaled to have a popula-
tion  average  of  1  (Supplementary  Methods  and  Supplementary 
Figure 1, available online). Because our SNP risk scores have been 
“centered” to have a population average risk of 1, if we assume 
independence among the seven SNPs, then the population average 
risk across all genotypes for the combined score is consistent with 
the underlying Gail risk estimate.
Statistical Analysis
We assessed the associations between different categories of clin-
ical risk factors and breast cancer risk using Cochran–Armitage 
trend  tests.  We  used  logistic  regression  to  assess  association 
between individual SNPs and breast cancer risk. We assumed a 
log-additive  allelic  model  for  genetic  associations,  as  described 
above.  We  also  used  logistic  regression  to  test  for  interactions 
between  pairs  of  SNPs  by  testing  for  statistical  significance  of 
model terms formed as the product of the individual SNP risk 
terms. We used likelihood ratio tests for comparing nested logistic 
regression models; these tests are one-sided but do not make as-
sumptions about the sign of the relationship between the depen-
dent and independent variables. All other P values were two-sided, 
and unless otherwise noted, P values less than or equal to .05 were 
considered statistically significant.
We used logistic regression to estimate odds ratios and 95% 
confidence intervals (CIs) associated with the logarithms of Gail 
risk and SNP risk separately, and as combined into the Gail × SNP 
risk score. The intercept term in the logistic regression was unre-
stricted  and  allowed  the  analysis  to  adapt  to  case–control 
sampling.
The  Hosmer–Lemeshow  test  (31)  is  typically  used  to  assess 
calibration of absolute risk estimates in cohort data. Instead, we 
used the test to assess agreement between expected and observed 
relative risks in our case–control study. We calculated the expected 
numbers of case patients and control subjects using a model in 
which the log-odds for breast cancer depended directly on the es-
timated log-odds ratio for a particular risk score. Here, we fit a 
logistic regression model with a coefficient (b) equal to 1.0 for the 
risk score, in conjunction with a freely estimated location parameter 
to match the overall number of case patients in the case–control 
sampling. This approach is justified by early work (32) showing 
that  logistic  regression  parameter  estimates  under  case–control 
sampling  have  targets  that  differ  from  those  under  prospective 
Table 1. Seven genomic loci associated with invasive breast cancer*
First author, year  
(reference) SNP Gene†
Chromosomal  
location
Frequency of  
high-risk allele
Reported, OR  
(95% CI)‡
Easton, 2007 (5) rs2981582 FGFR2 10q26 0.38 1.26 (1.23 to 1.30)
Easton, 2007 (5) rs3803662 TOX3 16q12 0.25 1.20 (1.16 to 1.24)
Easton, 2007 (5) rs889312 MAP3K1 5q11 0.28 1.13 (1.10 to 1.16)
Stacey, 2007 (7) rs13387042 ― 2q35 0.50 1.20 (1.14 to 1.26)
Easton, 2007 (5) rs13281615 ― 8q24 0.40 1.08 (1.05 to 1.11)
Stacey, 2008 (8) rs4415084 FGF10 5p12 0.44 1.16 (1.10 to 1.21)
Easton, 2007 (5) rs3817198 LSP1 11p15 0.30 1.07 (1.04 to 1.11)
*  Characteristics of the loci from the cited genome-wide association studies. CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism. ― = 
a relevant gene has not been identified.
†  The seven SNPs are located in or near the following genes: FGFR2 (fibroblast growth factor receptor 2); TOX3 (TOX high-mobility group box family member 3, 
previously known as TNRC9); MAP3K1 (mitogen-activated protein kinase kinase kinase 1); FGF10 (fibroblast growth factor 10); LSP1 (lymphocyte-specific 
protein 1).
‡  Odds ratio per copy of the high-risk allele, as reported in the cited study.jnci.oxfordjournals.org    JNCI | Articles 1621
sampling  only  though  a  shift  in  the  logistic  regression  location 
parameter.
We assessed classification performance of Gail risk, SNP risk, 
and  Gail  ×  SNP  risk  using  ROC  curves.  Bootstrap  resampling 
(1000  replicates)  was  used  to  estimate  confidence  intervals  for 
AUC as well as empirical P values for differences in AUC. Each 
bootstrap replicate was formed by selecting at random from the 
original case patients and control subjects, allowing the same indi-
vidual to be selected more than once, to obtain the same total 
numbers of case patients and control subjects. We used the pcv-
suite software package (33) to compute age-adjusted ROC curves 
and AUC values by measuring performance within deciles of the 
cohort defined by age and averaging these results to obtain values 
for the entire cohort.
We also evaluated classification accuracy using reclassification 
tables (34,35) and quantified differences in classification by net 
reclassification improvement (NRI) (36). Although reclassification 
tables  are  most  intuitive  in  population-based  studies,  the  NRI 
metric remains useful in case–control studies because it is unaf-
fected by case–control sampling. NRI is the sum of the proportion 
of case patients moving to a higher-risk category minus the pro-
portion of case patients moving to a lower risk category, and the 
proportion of control subjects moving to a lower risk category 
minus the proportion of control subjects moving to a higher-risk 
category (36). For simple tests of the hypothesis (NRI = 0), we used 
an asymptotic Z test (36). We also used bootstrap resampling to 
evaluate 95% confidence intervals for NRI and to determine em-
pirical P values for differences in NRI. We used the same boot-
strap samples for each classifier and used paired tests to compare 
classification performance to preserve the correlation structure of 
the classifiers.
We recently learned (N. Cook, personal communication) that 
NRI may be biased when calculated within a limited range of risk 
scores. Where this bias would be relevant, we determined an em-
pirical distribution of NRI under the null hypothesis using per-
muted risk scores and evaluated statistical significance of the actual 
NRI by comparison with this distribution.
Results
Characteristics of Case Patients and Control Subjects in the 
Nested Case–Control Cohort
Clinical characteristics of the 1664 case patients and 1636 control 
subjects selected from the WHI Clinical Trial that were success-
fully genotyped are summarized in Table 2. Most breast cancer 
risk factors that contribute to the Gail model were differentially 
distributed in the case patient and control subject groups, including 
age at menarche (Ptrend = .02), age at birth of first child (Ptrend = 
.004), first-degree relatives with breast cancer (Ptrend = .0001), and 
number of previous breast biopsies (Ptrend = 1 × 10
25). Age was not 
associated with case patient vs control subject status (Ptrend = .84) 
because ages were matched in case patients and control subjects.
Assessment of Association Between Individual SNPs and 
Invasive Breast Cancer Risk
The seven selected SNPs were genotyped across genomic DNA 
samples from trial participants using a custom array (Affymetrix, 
Inc, Santa Clara, CA) and/or the Sequenom MassARRAY iPLEX 
platform (Supplementary Methods, available online). There were 
few missing genotypes because of unsuccessful genotype measure-
ments (Table 3, and Supplementary Methods, available online).
We verified that the seven SNPs in this panel showed associa-
tions with breast cancer risk that were consistent with the prespeci-
fied parameters in our SNP risk model (Table 1). Five of the seven 
SNPs showed statistically significant association with breast cancer 
risk in our case–control cohort (Table 3). All seven SNPs had esti-
mated allelic odds ratios that were well within the range of previ-
ously reported confidence intervals (Table 3).
Table 2. Demographic characteristics and Gail model clinical risk 
factors for breast cancer in the nested case–control cohort*
Characteristics
Case 
patients,  
No. (%)
Control  
subjects,  
No. (%) Ptrend†
Total 1664 (100) 1636 (100)
ER status
  ER-positive tumor 1218 (73.2)  
  ER-negative tumor 208 (12.5)  
  Unknown‡ or missing§ 238 (14.3)  
Age at screening, y     .84
  50–59 510 (30.6) 510 (31.2)
  60–69 789 (47.4) 767 (46.9)
  70–79 365 (21.9) 359 (21.9)
  Missing§ 0 (0.0) 0 (0.0)
Age at menarche, y     .02
  <12 379 (22.8) 349 (21.3)
  12 441 (26.5) 407 (24.9)
  13 497 (29.9) 481 (29.4)
  ≥14 338 (20.3) 395 (24.1)
  Missing§ 9 (0.5) 4 (0.2)
Age at birth of first child, y     .004
  <20 182 (10.9) 214 (13.1)
  20–24 625 (37.6) 665 (40.6)
  25–29 370 (22.2) 349 (21.3)
  ≥30 151 (9.1) 117 (7.2)
  No term pregnancy 200 (12.0) 166 (10.1)
  Missing§ 136 (8.2) 125 (7.6)
Age at menopause, y     .52
  <45 300 (18.0) 294 (18.0)
  45–49 355 (21.3) 390 (23.8)
  50–54 646 (38.8) 596 (36.4)
  >54 238 (14.3) 237 (14.5)
  Missing§ 125 (7.5) 119 (7.3)
First-degree relatives with  
    breast cancer
    .0001
  0 1253 (75.3) 1319 (80.6)
  >1 309 (18.6) 226 (13.8)
  Missing§ 102 (6.1) 91 (5.6)
Number of previous breast  
    biopsies
    1 × 10
25
  0 1056 (63.5) 1148 (70.2)
  1 298 (17.9) 188 (11.5)
  >2 102 (6.1) 83 (5.1)
  Missing§ 208 (12.5) 217 (13.3)
*  The nested case–control cohort was selected from the Women’s Health 
Initiative (WHI) Clinical Trial. ER = estrogen receptor.
†  Ptrend values were calculated using the two-sided Cochran–Armitage test for 
trend.
‡  Pathology data on tumor ER status was unavailable or indeterminate.
§  Data for the specified characteristic was not available from the WHI Clinical Trial.1622   Articles | JNCI  Vol. 102, Issue 21  |  November 3, 2010
We  used  logistic  regression  to  test  for  pairwise  interactions 
among the seven SNPs. We did not detect any statistically signifi-
cant interactions; 21 distinct pairwise tests showed one test with   
P < .05 and none with P < .01 (data not shown). However, this study 
was only powered to detect relatively strong pairwise interactions.
Independence of Gail Risk and SNP Risk
The validity of our combined Gail × SNP risk score relied on the 
independence of Gail risk and SNP risk. Gail risk and SNP risk 
were tested separately for association with breast cancer incidence 
by logistic regression with log-transformed predictors. Both were 
strongly and statistically significantly associated with breast cancer 
(Table 3). Estimation of breast cancer risk with the SNP risk score 
gives  relative  risk  estimates  roughly  proportional  to  observed 
disease rates (Table 4). The Gail risk and SNP risk were weakly 
but statistically significantly correlated (Pearson correlation [r] = 
0.042, P = .02). The combined predictor formed by multiplying 
the Gail risk by the SNP risk (Gail × SNP risk) was more strongly 
associated with breast cancer risk than either component alone 
(Table 4). Including log-transformed Gail risk and SNP risk as 
separate terms in the logistic regression model further improved 
the fit (P = 2.3 × 10
25) by accommodating the difference in calibra-
tion of the two terms. However, in a model with these separate 
terms, an interaction term did not further improve prediction of 
breast cancer status (P = .5) (data not shown in Table 4).
To visualize the properties of SNP risk for different Gail risk 
categories, we binned the Gail risk and SNP risk scores into quin-
tiles and evaluated the relationship between SNP risk and the odds 
of developing breast cancer within each Gail risk stratum (Figure 1). 
The SNP risk was consistently associated with breast cancer within 
each  stratum.  This  showed  further  evidence  that  Gail  risk  and 
SNP risk provided independent information about risk.
A linear regression model was used to test whether the log-
transformed SNP risk score was predictive of any of the clinical 
risk factors contributing to the Gail model, while adjusting for 
case–control status. The SNP risk score was not statistically signif-
icantly associated with age at menarche (P = .96), age at menopause 
(P = .78), number of first-degree relatives with breast cancer (P = 
.20), or number of previous breast biopsies (P = .41). The SNP risk 
score was possibly associated with age at first birth (P = .10), and 
this association appeared to be specifically mediated by rs2981582 
in the fibroblast growth factor receptor 2 (FGFR) gene. This SNP 
alone showed stronger evidence for association (P = .008) and was 
the only SNP associated with any clinical risk factor of the Gail 
model with P < .05 (data not shown). When only the control sub-
jects were analyzed, age at first birth was still statistically signifi-
cantly associated with SNP risk (P = .03) and with SNP rs2981582 
(P = .002), and there were no other associations of clinical risk 
factors and SNP risk with a nominal P value of less than .05. These 
findings would not remain statistically significant after correction 
Table 3. Associations between single-nucleotide polymorphisms (SNPs) and invasive breast cancer in case patients and control sub-
jects from the Women’s Health Initiative Clinical Trial*
SNP Call rate† PHWE‡
Frequency of  
high-risk allele Observed, OR (95% CI)§ P║
rs2981582 1.000 .29 0.41 1.35 (1.22 to 1.50) 2.9 × 10
29
rs3803662 1.000 .85 0.29 1.20 (1.08 to 1.34) 8.1 × 10
24
rs889312 0.996 .64 0.28 1.24 (1.12 to 1.38) 6.7 × 1025
rs13387042 0.910 .58 0.51 1.16 (1.05 to 1.29) 3.6 × 1023
rs13281615 1.000 .43 0.42 1.08 (0.98 to 1.20) .11
rs4415084 0.997 .07 0.40 1.18 (1.06 to 1.30) 1.5 × 10
23
rs3817198 1.000 .60 0.32 1.11 (1.00 to 1.23) .06
*  Associations were analyzed by univariate logistic regression for predicting breast cancer from the specified SNP genotype under a log-additive allelic model. CI = 
confidence interval; HWE = Hardy–Weinberg equilibrium; OR = odds ratio.
†  The proportion of individuals for whom a genotype was successfully determined, for a particular SNP.
‡  P values for Hardy–Weinberg equilibrium were calculated using a one-sided likelihood ratio test.
§  Odds ratio per copy of the high-risk allele in the case–control sample.
║  P values for tests of association were calculated using a one-sided likelihood ratio test.
Table 4. Association of Gail risk, single-nucleotide polymorphism (SNP) risk, and Gail × SNP risk with invasive breast cancer*
Predictor† b‡ (95% CI)
OR (95% CI) per twofold  
increase in risk score§ P║
log (Gail risk) 0.46 (0.30 to 0.63) 1.38 (1.23 to 1.54) 1.8 × 1028
log (SNP risk) 1.11 (0.86 to 1.36) 2.16 (1.82 to 2.57) 6.4 × 10219
log (Gail risk × SNP risk) 0.65 (0.51 to 0.78) 1.57 (1.42 to 1.72) 3.3 × 10221
*  Univariate logistic regression analysis for predicting invasive breast cancer from the specified risk scores. CI = confidence interval; OR = odds ratio.
†  The risk score used to predict invasive breast cancer.
‡  The logistic regression coefficient for the specified predictor.
§  The fitted odds ratio corresponding to a twofold increase in the risk score, equal to 2b.
║  The P values were calculated using a one-sided likelihood ratio test for including the predictor term in the model vs not including the predictor term.jnci.oxfordjournals.org    JNCI | Articles 1623
for multiple testing; hence, they require replication and validation 
in other datasets.
Calibration of the SNP Risk Score
To assess calibration of the SNP risk score, we used the Hosmer–
Lemeshow  test  (31),  which  compares  expected  and  observed 
counts  of  case  patients  and  control  subjects  in  deciles  of  risk 
(Supplementary Table 1, available online). As shown in Figure 2, 
the SNP risk score appeared to be well calibrated (P = .18). The 
Gail risk score, however, was not well calibrated (P = 1.6 × 1026), 
and this lack of calibration carried over to the Gail × SNP risk 
score to an intermediate extent (P = .003). These results were con-
sistent with our analysis using a logistic regression model, where a 
twofold increase in Gail risk showed only a 1.38-fold increase in 
cancer incidence (Table 4). The relatively poor calibration of the 
Gail risk score is consistent with a previous report from the WHI 
observational study (23). We did not observe an improvement in 
calibration in the subset of women with no missing observations 
for Gail risk factors.
Classification Performance of the Gail × SNP Risk Score
To assess the ability of the Gail × SNP risk score to better classify 
women’s breast cancer risk, we used the ROC curve analysis. We 
compared classification performance using the Gail risk score, the 
SNP  risk  score,  and  the  Gail  ×  SNP  risk  score  (Figure  3).   
We observed an AUC of 0.594 (95% CI = 0.575 to 0.612) for the 
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Figure 1. Observed odds of breast cancer for quintiles of single-nucleotide polymorphism (SNP) risk, stratified by Gail risk quintile (open circles). 
The overall odds of breast cancer in our study for case patients and control subjects were 1:1 because equal numbers of case patients and control 
subjects were selected. Quintiles of Gail and SNP risk are labeled 1–5 from lowest to highest risk. The straight lines represent linear least squares 
fits to the data within each Gail risk stratum. SNP risk was consistently associated with breast cancer odds within the Gail risk strata.
Expected proportion
O
b
s
e
r
v
e
d
 
p
r
o
p
o
r
t
i
o
n
0.3
0.4
0.5
0.6
0.7
0.3 0.4 0.5 0.6 0.7
Expected proportion
O
b
s
e
r
v
e
d
 
p
r
o
p
o
r
t
i
o
n
0.3
0.4
0.5
0.6
0.7
0.3 0.4 0.5 0.6 0.7
Expected proportion
O
b
s
e
r
v
e
d
 
p
r
o
p
o
r
t
i
o
n
0.3
0.4
0.5
0.6
0.7
0.3 0.4 0.5 0.6 0.7
A B C
Figure 2. Observed vs expected proportions of case patients, for deciles of risk scores. A) Gail risk. B) The single-nucleotide polymorphism (SNP) 
risk score. C) The combined Gail × SNP risk score (risk score = open circles). If the risk scores are calibrated, the open circles should fall along the 
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difference = 0.025 to 0.051, empirical P < .001). We also computed 
age-adjusted ROC curves, and all age-adjusted AUC values were 
within 0.001 of the unadjusted values (data not shown).
We used a reclassification table to assess the assignment of 
women to low, intermediate, and elevated risk categories. We 
chose 5-year absolute risk thresholds of 1.5% and 2% (<1.5% for 
below average risk, 1.5%–2.0% for intermediate risk, and >2.0% 
for elevated risk) and evaluated reclassification for the Gail × SNP 
risk score vs Gail risk score alone (Table 5). The Gail × SNP risk 
score assigned more individuals to the tails of the risk distribution: 
it placed 22% fewer case patients and 29% fewer control subjects 
in the intermediate 1.5%–2.0% bin compared with the Gail score 
alone. The NRI for this table was 0.085 (Z = 4.3, P = 1.0 × 10
25), 
indicating  that  these  changes  are  often  in  the  right  direction. 
Classification improved for 5.6% of case patients (P = 4.8 × 10
25) 
and 2.9% of control subjects (P = .018). Next, we investigated the 
extent to which reclassification performance might be distorted 
by poor calibration of the Gail model in the WHI cohort. We 
used a logistic regression model to fit breast cancer status against 
the logarithm of the 5-year Gail risk estimate to obtain recali-
brated Gail risk estimates. This has no effect on model discrimi-
nation, but the Hosmer–Lemeshow test suggested that the scores 
were now well calibrated (P = .87, compared with the previous 
P = 1.6 × 10
26). We adjusted the classification cut points to repre-
sent the same quantiles on this new risk scale. The NRI for this 
table was 0.099 (Z = 4.2, P = 1.3 × 10
25), with improvement for 
7.9% of case patients (P = 1.4 × 10
26) and 2.0% of control subjects 
(P = .11).
Reclassification performance is sensitive to the number of clin-
ically  meaningful  risk  categories  because  binning  of  risk  scores 
conceals improvements in risk estimates that do not cross the pre-
specified thresholds. If risk thresholds at 1.2%, 1.5%, 1.8%, and 
2.4% are chosen to distribute women into quintiles of Gail risk, 
then NRI increases to 0.141 (Z = 5.63, P = 9.0 × 10
29). For deciles 
of Gail risk, NRI is 0.182 (Z = 6.2, P = 2.1 × 10
210). The NRI is 
only weakly dependent on the precise placement of the cut points 
(Supplementary Figure 2, available online).
The usefulness and cost-effectiveness of a genetic test can be 
improved by avoiding testing individuals whose status is unlikely 
to change as a result of the test. Individuals who are far from the 
classification cut points are unlikely to be reclassified as a result of 
the test, and therefore, it is less efficient to test them. Therefore, 
excluding the tails of the risk distribution from the tested popula-
tion should result in an improved NRI, with reclassification of a 
higher proportion of tested individuals (37). We evaluated NRI 
across  a  grid  of  possible  lower  and  upper  bounds  of  Gail  risk. 
Excluding women in the tails of the risk distribution resulted in 
higher  NRI  (Supplementary  Figure  3,  available  online).  If  all 
women with Gail risk less than 1.5% or greater than 2.0% were 
excluded, then NRI improved to 0.195 (Z = 3.8, P = 8.6 × 10
25). To 
address a possible bias in the NRI estimate, we determined the 
empirical  distribution  of  NRI  from  25 000  replicate  datasets, 
where we recalculated Gail × SNP risk using permuted SNP risk 
scores. The mean NRI for women with Gail risk between 1.5% 
and 2.0% in these replicates was 0.024. Our observed NRI ad-
justed for this bias was 0.171 and remained statistically significant 
(empirical P = .0004).
combination of Gail × SNP risk compared with AUC of 0.557 
(95% CI = 0.537 to 0.575) for Gail risk alone and AUC of 0.587 
(95% CI = 0.567 to 0.607) for SNP risk alone. The difference in 
AUC for the combined risk score vs Gail risk score alone was sta-
tistically significant (difference in AUC = 0.037, 95% CI of the 
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Figure 3. Receiver operating characteristic curves and area under the 
curve (AUC) for Gail risk, single-nucleotide polymorphism (SNP) risk, 
and combined Gail × SNP risk.
Table 5. Reclassification for Gail risk vs combined Gail × single-
nucleotide polymorphism (SNP) risk*
Gail risk
Gail × SNP risk
<1.5% 1.5%–2.0% >2.0% Overall†
<1.5%
  Women 1060 241 64 1365
  Case patients 455 133 41 629
  Control subjects 605 108 23 736
  Proportion of cases 0.429 0.552 0.641 0.461
1.5%–2.0%
  Women 351 342 263 956
  Case patients 155 172 157 484
  Control subjects 196 170 106 472
  Proportion of cases 0.442 0.503 0.597 0.506
>2.0%
  Women 43 129 807 979
  Case patients 19 64 468 551
  Control subjects 24 65 339 428
  Proportion of cases 0.442 0.496 0.580 0.563
Overall‡
  Women 1454 712 1134 3300
  Case patients 629 369 666 1664
  Control subjects 825 343 468 1636
  Proportion of cases 0.433 0.518 0.587 0.504
*  Reclassification of case patients and control subjects selected from the 
Women’s Health Initiative clinical trial as a result of incorporating genetic 
information from seven SNPs into the Gail model. Reclassification was calcu-
lated for strata of absolute 5-year risk of <1.5%, 1.5%–2.0%, and >2.0%.
†  Counts of women, case patients, and control subjects, and the proportion of 
case patients aggregated across the three strata of Gail × SNP risk.
‡  Counts of women, case patients, and control subjects, and the proportion of 
case patients, aggregated across the three strata of Gail risk.jnci.oxfordjournals.org    JNCI | Articles 1625
Performance in Women With Previous Breast Biopsies
Because women with previous breast biopsies are at intermediately 
elevated risk of breast cancer and in particular need of risk stratifi-
cation to guide future screening and preventative strategies, we 
also assessed the impact of the Gail × SNP risk score in this subset. 
Given the loss of an important risk stratifier, the Gail model had 
an AUC of only 0.514 (95% CI = 0.471 to 0.561) in this subset. 
The Gail × SNP risk score had an AUC of 0.571 (95% CI = 0.526 
to 0.614). We also computed reclassification metrics in the biopsy 
subset (Supplementary Table 2, available online). In this subset, 
the  NRI  is  0.175,  which  is  statistically  significant  despite  the 
smaller number of events (Z = 3.9, P = 4.9 × 1025). The classification 
improved for only 2.8% of case patients (P = .16) but for 14.8% of 
control subjects (P = 1.5 × 1025). We used bootstrap resampling to 
evaluate whether the difference in NRI between the full cohort, 
and the biopsy subset was statistically significant. Based on 1000 
bootstrap replicates, a 95% confidence interval for the improve-
ment  in  NRI  in  the  biopsy  subset  extended  from  0.02  to  0.16 
(empirical P = .03). This increase in NRI is not simply a conse-
quence of conditioning on an important Gail risk factor; in the 
subset of individuals without a previous breast biopsy, NRI was 
reduced to 0.065.
Risk Assessment and Tumor ER Status
We evaluated risk assessment among subsets of breast cancer case 
patients defined by ER status (Supplementary Results, available 
online). Gail risk and Gail × SNP risk were substantially more 
predictive for ER-positive (Gail risk: P = 1.1 × 10
29; Gail × SNP 
risk: P = 2.4 × 10
222) than for ER-negative tumors (Gail risk: P = 
0.89; Gail × SNP risk: P = 0.32) (Supplementary Tables 3 and 4, 
available online). We saw suggestive evidence that an SNP risk 
model using ER-specific odds ratios may improve performance for 
ER-negative tumors (improvement in AUC = 0.022, empirical P = 
0.10) (Supplementary Table 5, available online).
Discussion
The major finding from this nested case–control cohort from the 
WHI Clinical Trial is that genetic risk information may be com-
bined  multiplicatively  with  Gail  risk  scores  to  improve  breast 
cancer  risk  estimation  in  postmenopausal  white  non-Hispanic 
women. This finding is based both on the observation that breast 
cancer risk may be accurately estimated by combining published 
SNP  risk  estimates  and  also  the  observation  that  correlation 
between  SNP  risk  scores  and  Gail  risk  for  individuals  is  weak, 
allowing  breast  cancer  risk  to  be  more  accurately  estimated  by 
combining  SNP  risk  and  Gail  risk  multiplicatively.  Thus,  this 
study supports the claim that the combined risk estimation model 
approach has clinical validity in the broad sense in postmenopausal 
white non-Hispanic women.
The calibration and discrimination of the Gail model in the 
WHI cohort are known to be somewhat worse than those seen in 
other large studies (23). This is likely because of a combination of 
factors, including higher mammography rates, differences in age 
distributions, and changes in breast biopsy procedures, with more 
common  use  of  image-guided  percutaneous  core  biopsy  proce-
dures that have a lower threshold for use than open biopsy (23). 
The lack of data on atypical hyperplasia may also contribute to 
lower  calibration  and  discrimination  in  the  WHI  cohort. 
Additionally,  as  the  WHI  Clinical  Trial  tested  the  impact  of 
hormone replacement therapy on breast cancer risk, a higher per-
centage of women in our case–control cohort may have received 
hormone replacement therapy than in the studies in which the Gail 
model  was  previously  validated.  Last,  the  age  matching  in  our 
nested  case–control  study  is  likely  to  have  contributed  to  the 
reduced performance of the Gail model because age plays a sub-
stantial role in that model. This limitation does not directly affect 
our assessment of independence and calibration of the SNP risk 
scores but may affect the quantitative metrics of improvement in 
risk assessment in the combined model. Reclassification perfor-
mance is sensitive to model calibration as well as discrimination, 
and it will need to be further characterized in population-based 
cohorts.
When we assessed the performance of a combined risk pre-
dictor incorporating both the Gail risk and SNP risk, the com-
bined risk predictor performed better in predicting breast cancer 
risk  than  either  Gail  risk  or  SNP  risk  alone.  By  ROC  curve 
analysis,  the  AUC  for  Gail  and  SNP  risk  combined  was  0.594 
(95%  CI  =  0.575  to  0.612)  as  compared  with  Gail  risk  alone, 
showing an AUC of 0.557 (95% CI = 0.537 to 0.575). Although 
this statistically significant improvement was modest, in this data-
set, the Gail model itself had an AUC that was only 5.7% greater 
than that expected by chance.
Although ROC curves are useful in some contexts, they have 
been criticized for several reasons: 1) they summarize classification 
information across the full range of sensitivities and specificities (in 
most clinical contexts, only a subset of these sensitivities and spec-
ificities are relevant); 2) they do not provide information about the 
actual risks predicted by the model; 3) they do not provide infor-
mation about the proportion of individuals with particularly high- 
or low-risk values; and 4) the area under the ROC curve, which is 
the probability that a predicted risk for an individual with an event 
is  higher  than  for  an  individual  without  an  event,  has  minimal 
direct clinical relevance (38). Therefore, we used reclassification 
tables (34,35) to calculate NRI (36) as a more helpful measure of 
the potential impact of the Gail × SNP risk score in assessing in-
vasive breast cancer risk (27). This analysis demonstrated a statis-
tically significant improvement in classification (NRI = 0.085; P = 
1.0 × 10
25). Importantly, NRI can be substantially improved by 
focusing SNP genotyping on those individuals who are predicted 
to be at intermediate risk by the Gail score, as these women are 
most likely to be reclassified after the addition of SNP risk. For 
example, limiting SNP testing to women with Gail 5-year risks 
between 1.5% and 2.0% results in a substantially larger NRI of 
0.195. Taking this information into account, future efforts should 
rigorously  evaluate  the  clinical  utility  of  targeted  strategies  to 
incorporate  the  combined  risk  score  into  the  clinical  decision-
making process in the context of both breast cancer primary pre-
vention and screening (17220).
NRI is a relatively new statistic but has gained increasing accep-
tance as an important part of the evaluation of new biomarkers and 
risk stratifiers (38,39). The statistic has also been criticized, for 
sensitivity to model calibration (40,41) and dependence on arbi-
trary cut points (42). The use of NRI presupposes that classification 1626   Articles | JNCI  Vol. 102, Issue 21  |  November 3, 2010
performance is important, and in that context, sensitivity to cali-
bration could be seen as a feature, not a limitation. In any case, the 
Gail model is embedded within our combined risk model, so the 
calibration  discrepancy  of  the  Gail  model  is  also  present  in   
the combined model. We obtained a similar NRI using recali-
brated Gail risk estimates, and we found that the NRI statistic is 
robust to moderate changes in the cut points.
We  also  evaluated  whether  it  might  be  possible  to  obtain 
better  test  performance  by  focusing  on  a  subset  of  women  at 
particularly  high  risk—those  with  previous  breast  biopsies 
(43,44).  Here,  classification  improved  for  only  2.8%  of  case 
patients  but  for  14.8%  of  control  subjects  (P  =  4.4  ×  10
25). 
Although this improvement suggests that the combined Gail × 
SNP risk score might assist in identifying a subset of women with 
previous biopsies who might not need as aggressive risk reduction 
and  surveillance  efforts  as  their  biopsy  history  suggests,  these 
results should be interpreted with caution and will require further 
validation in other datasets with available histopathology from 
the previous biopsies.
This study has several strengths. First, we have taken a rigorous 
approach to identifying the SNPs to include in the panel; only 
including those that have been reproducibly associated with breast 
cancer  risk  and  for  which  consistent  risk  estimates  have  been 
reported in the literature (528). Second, we have genotyped indi-
viduals from a large prospectively recruited cohort with meticulous 
data collection and rigorous ascertainment of relevant breast can-
cer outcomes. Third, we have used literature-based genetic risk 
estimates and have combined them in a straightforward fashion to 
form risk predictors. Importantly, we did not train our predictors 
on the WHI Clinical Trial data and only used the trial samples to 
assess their performance.
Our study has a few limitations that include the composition of 
the WHI Clinical Trial cohort, which limits inferential scope to 
white non-Hispanic postmenopausal women, and the clinical char-
acteristics of the women therein. For example, individuals within 
the WHI Clinical Trial received hormone replacement therapy at 
a  higher  frequency  than  women  currently  do  at  present. 
Importantly, the age-matching design inherent to this study does 
remove one of the Gail model variables and contributes both to the 
relatively low AUC seen for the Gail model in our analysis and to 
its poor calibration. In addition, the absence of pathology records 
for previous breast biopsies in the WHI Clinical Trial required us to 
estimate individual Gail risks by coding atypical hyperplasia status 
as unknown for women with prior breast biopsies. Although the 
incidence of atypical hyperplasia is sufficiently low that it seems 
unlikely to have affected the analyses of the entire nested case–
control study, it is unclear to what extent this may have affected 
the analyses focusing on the subset of women with one or more 
previous biopsies. Additionally, case–control sampling means we 
cannot evaluate calibration of absolute event rates; we can only 
effectively test the slope of the relationship between expected and 
observed risk and not the intercept. Therefore, although the WHI 
Clinical Trial cohort is sufficient to support the validity of the 
SNP risk and Gail × SNP risk models in predicting breast cancer 
risk, there is a need for further assessment of the clinical validity 
of the combined Gail × SNP risk model, especially in population-
based cohorts.
A recent study (29) has performed a similar evaluation of breast 
cancer risk models incorporating SNP information, which com-
bined case patients and control subjects from four cohort studies 
and  one  case–control  study  (including  the  WHI  Observational 
Study), and refit Gail and SNP model parameters rather than 
comparing prespecified models. It reported a difference in AUC of 
0.038 from adding SNP information to the best clinical risk model 
compared with 0.037 in our study. Although NRI itself was not 
reported, it can be calculated from the reported data for quintiles 
of risk, and the resulting NRI of 0.141 matches our result. These 
results suggest that our reported differences in model performance 
are somewhat robust to differences in underlying data and model-
fitting methodologies.
The use of improved risk models, such as the one described in 
our study, may benefit the public health if shown to have clinical 
utility when combined with optimal individualized screening and 
risk reduction strategies. We agree with previous assessments that 
the benefits are likely to be modest (26,29), although our work 
points to several strategies that may give better results. A previous 
evaluation of potential utility considered an unselective strategy 
for SNP testing broadly applied to women regardless of Gail risk 
(26). Our results suggest that, because utility is sensitive to how a 
test is targeted, it may be wise to focus further evaluation of the 
application of SNP genotyping for breast cancer risk on women at 
intermediate risk as measured by the Gail model. Such a strategy 
clearly  boosts  classification  performance  in  this  study.  Use  of 
broad  highly  multiplexed  multi-disease  SNP  panels  would  also 
improve  cost-effectiveness  by  reducing  the  marginal  cost  of 
testing. Future research should assess performance in population-
based  cohorts  and  ultimately  address  whether  classification  im-
provement  can  be  translated  into  improved  prevention  and/or 
screening outcomes in the clinic.
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